World Class Research

As the largest private funder of pancreatic cancer research, we are relentlessly focused on improving patient outcomes and we are making progress every day. Thanks to separate funding to support administrative expenses, 100 percent of every donation goes directly to research.

Navigating Pancreatic Cancer

We are here to empower you to ask bold questions, seek out the best treatment options, and face the unique challenges of pancreatic cancer head-on. We want to give you the resources and information you need to make informed decisions that are best for you.

Patient Checklist

Checklist

August 1, 2018 ladmin

As overwhelming as a pancreatic cancer diagnosis is, it is important to act quickly and put a treatment plan into place. Treatment should ideally begin within one month after you receive your diagnosis. Understand your disease. Thoroughly understand what stage of pancreatic cancer you have and inquire about having your blood and tumor genetically sequenced. […]

Research

Clinical Trials Finder

July 30, 2018 ladmin

If you have been diagnosed with pancreatic cancer, a clinical trial may be your best treatment option. Many clinical trials are underway for patients in all stages of the disease and may involve new combinations of currently available drugs or new drugs that have worked in other cancers. No matter where you are in your journey, we encourage you to learn more about clinical trials.

Lets Win! Pancreatic Cancer

Let’s Win! Pancreatic Cancer

July 20, 2018 ladmin

LET’S WIN! Pancreatic Cancer A Dynamic Way to Share Information Recognizing that there is an urgent need for patients to communicate amongst themselves and with the medical community about potentially life-changing treatments and clinical trials, we are proud to be affiliated with Let’s Win. Let’s Win is an interactive online community where patients and families […]

Pancreatic Cancer Connections

July 7, 2018 ladmin

Pancreatic Cancer Connections is online social community that provides a safe space for pancreatic cancer patients and their loved ones to share their experiences, get valuable coping resources, and support one another. Patients interact with others who are facing a pancreatic cancer and can post questions to the board or message other members privately. This community forum is a valuable resource for patients, caregivers, and their loved ones to refer to at various stages of their treatment and recovery.

Patients and loved ones can sign up for Pancreatic Cancer Connections at no cost and will be welcomed into an engaging and supportive community to discuss topics including treatment options, nutrition, and coping with the disease. Pancreatic Cancer Connections is hosted by Inspire, a leading healthcare social network that connects more than 1,000,000 patients and caregivers.

Lustgarten News


SU2C Telecast

We were so proud to be highlighted during the sixth bi-annual SU2C telecast.   Patients like Lidia motivate and inspire us each and every day.  The words that Katie Couric spoke were so powerful and true.  Pancreatic Cancer is personal.  That is why we created the Pancreatic Cancer Collective.  Through our collaboration, we have funded NINE pancreatic cancer research teams.  And later this fall, for the first time, we will be funding teams to use Artificial Intelligence to learn how to find pancreatic cancer at much earlier stages than it has been typically diagnosed.

Since 2012, the Lustgarten Foundation and Stand Up To Cancer have built a robust and illustrious collaboration jointly funding more than 200 investigators across 30 leading research centers in both the United States and United Kingdom. These efforts include four of SU2C’s signature Dream Teams as well as five Research Teams, including two Convergence Teams bringing together computational experts with clinical oncologists. Cancer Interception, research supporting the earliest diagnosis of pancreatic cancer, even before the cancer may have fully formed is the focus of one of the Dream Teams and one of the Research Teams. All told, these collaborative teams have planned, started or completed 23 clinical trials. The Pancreatic Cancer Collective will build on this momentum and push the boundaries of what can be accomplished even further.

Through the Collective, we will create a dynamic and fluid network to engage and influence medical institutions, researchers, companies, aligned to achieve something bigger and more meaningful, in particular to:

  • Inspire collaboration among people who haven’t worked together
  • Spread funding to new centers
  • Improve diagnosis of Pancreatic Cancer using big data
  • Find new medicines for Pancreatic Cancer
  • Utilize the breadth and expertise of existing Teams and researchers supported by SU2C and the Lustgarten Foundation to support new investigators coming into the field, building expertise and capacity for additional research.

Learn more about the Collective.

Learn More

Lustgarten Labs in the Boston Herald

The Lustgarten Foundation is pleased to announce two new dedicated pancreatic cancer research laboratories through respective partnerships with Dana-Farber Cancer Institute and Massachusetts Institute of Technology (MIT). The opening of these Lustgarten Foundation Pancreatic Cancer Research Laboratories will usher in a new era of research progress and represents an initial $10 million investment. These laboratories position the Foundation to be the only non-profit in the country to have three laboratories devoted to pancreatic cancer research.

“The addition of these two laboratories, along with our dedicated laboratory at Cold Spring Harbor Laboratory, will help us bring together the best science and research minds to foster and advance the goals of finding a cure for pancreatic cancer,” said David Tuveson, M.D., Ph.D., Chief Scientist and Director of the Lustgarten Foundation Dedicated Research Laboratory, and Director of the Cold Spring Harbor Laboratory Cancer Center at Cold Spring Harbor Laboratory.

United in the shared goal of improving patient outcomes, the laboratories will increase collaboration between world-renowned pancreatic cancer researchers and explore new, promising avenues for understanding and treating this disease from the bench to the bedside. At the time the Lustgarten Foundation was established in 1998, pancreatic cancer was indeed an “orphan” disease, with fewer than 15 researchers studying pancreatic cancer nationally. Twenty years later, and with the additions of these dedicated laboratories, thousands of researchers are now focused on pancreatic cancer.

At Dana-Farber, under the leadership of Brian Wolpin, M.D., MPH, Director of the Gastrointestinal Cancer Center, Director of the Hale Family Center for Pancreatic Cancer Research, and the Robert T. & Judith B. Hale Chair in Pancreatic Cancer, the Dana-Farber-Lustgarten Laboratory will be a critical hub for advancing pancreatic cancer translational research, initiating scientifically-driven clinical trials, and identifying new approaches to early pancreatic cancer detection. This work will also capitalize on the large, multidisciplinary network of investigators working on pancreatic cancer at the Dana-Farber, under the umbrella of the Hale Center.

The research conducted in the Lustgarten Laboratory at Dana-Farber will focus on three main objectives:

  • Study the genetic composition and functionally characterize the driver pathways of pancreatic tumors, which will lead to personalized treatment options for patients;
  • Expand clinical trials for patients with metastatic pancreatic cancer, in which treatments are selected using organoids, or miniature 3-D tissues samples taken from a patient’s tumor;
  • Organoids allow multiple drugs to be tested in real time to identify the best course of treatment for the patient; and
  • Identify new blood-based and imaging markers of asymptomatic pancreatic cancer and new models for pancreatic cancer risk prediction to facilitate earlier cancer detection.

The Lustgarten Laboratory at MIT will leverage its unparalleled expertise in cancer biology and engineering to advance pancreatic cancer research. Led by Tyler Jacks, Ph.D.,  Director of MIT’s Koch Institute for Integrative Cancer Research, Howard Hughes Medical Investigator, Daniel K. Ludwig Scholar and David H. Koch Professor of Biology, the laboratory will examine the immune responses to the disease using molecular profiling to characterize patients’ pancreatic tumors.

The main objectives of the Lustgarten Laboratory at MIT will be to:

  • Evaluate the role the immune system plays in the development of pancreatic tumors and progression of the disease to lead to better therapeutic options;
  • Explore pancreatic cancer progression using single cell profiling technologies, which will provide new insights into the mechanisms of disease development as well as identify new targets for intervention;
  • Reduce the time required to produce an organoid; and,
  • Use organoids and mouse models with specific mutations to examine genes that may be responsible for tumor development and explore DNA manipulation through screenings to examine disease progression.

Read more  in the  Boston Herald.

Learn More

Celebrating 20 Years

Our Story of Progress & Promise

As we reflect on the past 20 years of milestones and build on the momentum we’ve created in advancing the understanding and treatment of pancreatic cancer, we are pleased that we are more than a voice in the national dialogue on pancreatic cancer research; we started the conversation. As the nation’s largest private funder of pancreatic cancer research, we have the profound responsibility of shining a spotlight on pancreatic cancer and doing everything possible to improve the treatment of the disease. To that end, we have directed $165 million to research to date, and we are the only pancreatic cancer research organization that directs 100% of every donation to research.

In honor of the patients and their loved ones facing this life-threatening disease with tenacity and grace, the researchers in laboratories across the country, the clinicians on the front lines of treatment and the donors, sponsors and other supporters who wholeheartedly believe in our mission, we commemorate this 20th anniversary by looking back at our collective journey and rededicating ourselves to what matters most: improving patient outcomes.

The Need for a Pancreatic Cancer Research Foundation

In 1998, 51-year-old Marc Lustgarten, Vice Chairman of Cablevision, was diagnosed with pancreatic cancer. It quickly became evident that there were few therapy options, and research was practically non-existent. Pancreatic cancer was truly an orphan disease. There was only $16.2 million, or less than one half of one percent of the National Cancer Institute’s (NCI) multibillion dollar budget, allocated to researchers studying pancreatic cancer. Yet this disease was the nation’s fourth leading cause of cancer deaths.

Charles F. Dolan, Chairman of Cablevision, Marc, and Dr. Robert F. Vizza, former President and CEO of St. Francis Hospital, met to explore options to help Marc and to better understand the landscape of this disease. After evaluating the available treatment options and the state of pancreatic cancer research, they, along with James Dolan, President and CEO of Cablevision, developed a vision for a foundation dedicated to “advancing the scientific and medical research related to the diagnosis, treatment, cure and prevention of pancreatic cancer.” Initial funding was generously provided by Charles F. Dolan, and Dr. Vizza became President and CEO of the Lustgarten Foundation for Pancreatic Cancer Research.

To organize the Foundation, a Board of Directors, Scientific Advisory Board, and Corporate Advisory Board were established. Charles F. Dolan assumed the role of Chairman of the Board, a position which he held for almost 20 years, he is now Chairman Emeritus. A world-renowned Scientific Advisory Board comprised of researchers and clinicians from leading institutions across the country was created to guide our research funding strategy and activities. The Corporate Advisory Board, led by Honorary Chairman former President Jimmy Carter and joined by prominent cable and media executives, enabled the Foundation to promote its mission to millions of Americans.

Cablevision’s Support

Marc’s diagnosis and passing had a significant impact on everyone at Cablevision, which has been a strong supporter of the Foundation from the start. In fact, on October 4, 1999, Cablevision dedicated the Radio City Music Hall re-opening gala to mark the national launch of the Lustgarten Foundation. During the event, the Foundation’s Corporate Advisory Board announced its commitment to air PSA’s designed to heighten awareness of the need for increased research, with the initial PSA featuring former President Jimmy Carter.

Then, in 2008, Cablevision made a multi-year commitment to pay all the Lustgarten Foundation’s administrative expenses. This unique partnership ensured that 100% of every dollar donated went directly to pancreatic cancer research.

Cablevision also used its unique portfolio of high-profile media and entertainment assets to create disease awareness by joining with the Lustgarten Foundation to launch curePC, a public awareness campaign. President Carter was the first of many notable figures, including Danny Aiello, Joan Cusack, Michael Ealy, Dr. Sanjay Gupta, Felicity Huffman, Larry King, Matthew Modine, Rosie O’Donnell, Dr. Mehmet Oz and Dr. Randy Pausch, to record PSA’s for the Foundation. The PSA’s, along with media coverage of curePC’s campaign activities, reached millions of people and increased awareness of the Foundation and of the need for increased pancreatic cancer research.

Research Strategy

Working with the National Cancer Institute (NCI)

At a meeting with the Executive Director of the NCI in 1998, it was agreed that a program was needed to address the survival rate for pancreatic cancer. In 2000, the Foundation joined with the NCI to participate in the first ever NCI Pancreatic Cancer Progress Review Group (PRG) to develop a national agenda for pancreatic cancer research. Based on recommendations from the PRG, the NCI developed an action plan to increase support and funding for pancreatic cancer research. As part of this plan, the NCI committed to fund at least three Pancreatic Cancer Specialized Programs of Research Excellence (SPOREs) for five years, and the first three SPORE grants were awarded in 2003. This effectively more than doubled the annual commitment of the NCI to pancreatic cancer research. Over time, the Foundation’s support of pancreatic cancer research helped stimulate the NCI to increase its pancreatic cancer research funding to more than $152 million in 2016 and inspired the creation of other pancreatic cancer organizations.

Creating a Research Map

The Foundation’s initial research strategy was aimed at attracting researchers to the field of pancreatic cancer. To accomplish this, we sought out and funded researchers from around the world, many of whom have now made it their life’s work to better understand and treat this disease. We awarded a series of $100,000 grants and held scientific conferences, bringing together pancreatic cancer leaders to exchange ideas. The Lustgarten Foundation became the driving force in changing the pancreatic cancer research landscape.

We then developed a focused research strategy to identify critical areas of research that when successfully completed, will bring us more quickly to a cure. As part of this strategy, the Foundation invites leading scientists to submit research proposals that address early detection, new drug development and clinical trials. The competitive grants are reviewed by our SAB and then the best proposals receive funding.

As part of this focused research approach, we implemented a pancreatic cancer research map to strategically move key research initiatives forward. The research map represents a dynamic plan, which evolves as new areas of research are identified. Areas of focus, which continue to guide our research today, include earlier diagnosis and more effective treatment, with the goal of finding a cure.

Establishing Dedicated Pancreatic Cancer Research Laboratories
Once the research groundwork had been laid, we could now expand our efforts to start a world-class pancreatic cancer research laboratory at the Cold Spring Harbor Laboratory on Long Island. Founded in 1890 and home to eight Nobel Prize winners, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and was the ideal location to establish the first Lustgarten Foundation Dedicated Pancreatic Cancer Research Laboratory in 2012.

David Tuveson, M.D., Ph.D., a renowned pancreatic cancer expert, was brought on as the director. As a physician-scientist, Dr. Tuveson merges his laboratory and clinical research, enabling him to bring new options to patients more rapidly. Twenty-five scientists in the lab focus exclusively on pancreatic cancer, designing new models of the disease and discovering novel therapeutic and diagnostic platforms. To help meet the need for additional research, we are opening two more dedicated pancreatic cancer research laboratories in the fall of 2018.

Founding the Distinguished Scholar, Research Investigator, and Translational Clinical Grant Programs

In 2014, we launched two programs to stimulate new research. The Distinguished Scholar program supports scientists who are at the top in their field and are at the forefront of today’s most exciting breakthroughs in pancreatic cancer research. The Research Investigator program funds talented scientists with historical accomplishments in cancer research. Through these grants, the Foundation also attracted prominent scientists from other fields to study pancreatic cancer.

In 2017, we started the Translational Clinical grant program, which focuses on research “from the bench to the bedside” and funds new, innovative multi-institutional translational research projects.

Collaborating with Stand Up To Cancer

The Lustgarten Foundation – Stand Up To Cancer (SU2C) collaboration has played a critical role in promoting therapeutic discoveries that can lead to new treatments. This collaboration has flourished with now more than $85 million of combined funding. More than 170 investigators across 28 leading research centers in both the United States and the United Kingdom are conducting multicenter, multidisciplinary projects with explicit objectives to drive innovation to the clinic to tackle pancreatic cancer. Together, these collaborative teams have planned, started or completed 22 clinical trials.

Our first joint research project focused on Abraxane, which the FDA approved in 2012 in combination with gemcitabine as first line treatment for patients with advanced metastatic pancreatic cancer. This was the first new treatment approved in nine years and is now the standard of care for many patients.

In 2018 we joined forces to create the Pancreatic Cancer Collective to accelerate the research process and improve patient outcomes. Through the Collective, our two organizations are positioned to attract new collaborators; improve the diagnosis of pancreatic cancer; and support the next generation of pancreatic cancer investigators. The initial funding commitment for the first round of grants is $25 million with a commitment to continue over many years.

Research Milestones

Pancreatic cancer research is moving faster than ever before, and there has never been a more exciting or hopeful time for patients. Our Lustgarten-funded researchers have achieved significant milestones in understanding and treating this disease and in detecting the disease earlier – advancements that are already changing patient outcomes.

Mouse Model Created for Pancreatic Cancer and the Role of the Stroma

One of the most significant early advancements was achieved by our Chief Scientist, Dr. David Tuveson, during his tenure at the University of Pennsylvania. Dr. Tuveson generated the first genetically engineered mouse model for pancreatic cancer, a model which is now used throughout the scientific community to test new therapies for pancreatic cancer. He also discovered that pancreatic cancer tumors develop a protective membrane, or stroma, which prevents chemotherapy from reaching the cancer cells, impeding treatment.

Pancreatic Cancer Genome Project

To further understand the disease so it could be more effectively diagnosed and treated, in 2008 we funded renowned cancer researcher Dr. Bert Vogelstein of Johns Hopkins University’s Kimmel Cancer Center to lead the most comprehensive genetic sequencing that had ever been done for any cancer. The Pancreatic Cancer Genome Project was named one of the top three

“Breakthroughs of the Year” by Science. Dr. Vogelstein found that:

  • Pancreatic cancer is caused by a number of mutations acting together, rather than by a single gene;
  • Understanding the mutations offers the potential for new diagnostic tools and therapies;
  • Certain mutated pancreatic cancer genes are cancer-causing, while others are mutations that occur simply as a result of the cancer being formed;
  • The KRAS gene is mutated in nearly 100 percent of all pancreatic cancer tumors.

The Pancreatic Cancer Genome Project laid the groundwork for two major milestones to come later: the development of CancerSEEK, a blood screening test, and the use of Keytruda,® an immunotherapy treatment for advanced pancreatic cancer patients whose tumors are mismatch repair deficient.

Early Detection

Researchers led by Dr. Vogelstein designed a blood test called CancerSEEK and published data on this groundbreaking test in 2017. CancerSEEK can detect the presence of early pancreatic cancer and seven other cancers and identify the organ of origin of these cancers. This study lays the groundwork for a single blood screening test for multiple cancers, including pancreatic cancer, that could be offered as part of routine medical checks. The initial research for this blood test began in 2008, when we launched the $1.25 million Pancreatic Cancer Biomarker Development Project, the start of our long-standing Early Detection Initiative, with the goal of developing new earlier detection and screening methods and better imaging techniques.

“Years from now, death from cancers will be a lot less common, and that’s going to be in large part due to earlier detection.” – Bert Vogelstein, M.D., Lustgarten Foundation Distinguished Scholar

Immunotherapy

In an unprecedented, fast-tracked review, the FDA approved Keytruda® (pembrolizumab) as the first immunotherapy treatment for advanced pancreatic cancer patients whose tumors have a unique genetic mutation called mismatch repair deficiency that alters their capacity to repair DNA, which is a factor in cancer development. It is estimated that approximately 1 in 50 advanced pancreatic cancer patients has a tumor that is mismatch repair deficient. The approval of Keytruda® was named a runner-up for the prestigious “Breakthrough of the Year” award by Science in 2017.

Personalized Medicine and the Organoid

Another significant research achievement was Dr. Tuveson’s development of the organoid for pancreatic cancer, which brought the laboratory closer to the clinic. Organoids are three-dimensional cell culture systems which reproduce a patient’s tumor in a dish to test it repeatedly with different drugs, with the aim of identifying new treatments. Presently, it is difficult to determine how a patient will respond to a specific treatment and therefore, patients may be treated with drugs that they won’t respond to. In the laboratory, the organoid becomes the subject for testing. Researchers have demonstrated that organoids can accurately predict how patients with pancreatic cancer will respond to a variety of treatments. This translational technology offers the hope of personalized cancer treatments in the future.

In fact, working with Dr. Tuveson, Dr. Brian Wolpin, Dana-Farber Cancer Institute, is now personalizing treatment directly for patients to identify the best second-line treatment options. He is testing each patient’s organoid response to different therapies and genetically sequencing both the tumor DNA and the inherited DNA. The sequencing findings are then used for patients’ treatment, which may include using off-label use of medications that treat other cancers. Dr. Wolpin’s recent research findings have suggested that approximately one-third of pancreatic cancer patients may have a genomic alteration that could impact treatment decisions and guide doctors to choose a specific therapy for a personalized medicine approach.

Patient Support

As we continue to fund the most innovative research, we are also focused on serving as a resource for those impacted by pancreatic cancer. The Foundation created and began distributing a variety of free online and printed educational materials to help patients and loved ones make informed healthcare decisions. The Foundation also provides support directly to patients and caregivers who contact our Patient Information Coordinator. Moreover, we collaborate with an online, free clinical trial matching and referral service.

In 2016, Let’s Win! Pancreatic Cancer, an interactive online community, was founded as an unprecedented platform that enables doctors, scientists and patients to share fast-breaking information on potentially life-saving pancreatic cancer treatments and clinical trials. The goal is to provide actionable information all in one place. In 2017, to further help patients and their loved ones navigate their pancreatic cancer journey, we launched an online patient/caregiver support community, Pancreatic Cancer Connections, in partnership with Let’s Win! Pancreatic Cancer Foundation and Inspire, a leading healthcare social network.

Community Outreach

Recognizing the need to reach out directly to the pancreatic cancer community, we launched the Lustgarten Walk program, starting with one walk in Long Island in 2001, which attracted over 1,200 people and raised more than $140,000. Today, the program has raised more than $40 million, and we hold more than 40 walks annually in nearly 20 states in our quest for a cure. When our walk program started, our participants were walking in memory of loved ones lost to the disease; now, 20 years later, survivors attend our walks and community events, offering inspiration, hope and support to those who are going through the same journey.

To complement the walk program, the Foundation’s supporters began holding community events across the country to raise awareness and funding for pancreatic cancer research. Events included golf outings and other sporting events; weddings, anniversaries, and other milestone celebrations; social activities; and workplace initiatives. Nearly 300 events are held annually throughout local communities as well as large scale fundraisers.

For the past 17 years, the annual Holiday Rock & Roll Bash, initiated by Cablevision CEO James Dolan and hosted by Cablevision, The Madison Square Garden Company and AMC Networks, has attracted thousands of attendees and has raised a cumulative total of nearly $24 million for research. In 2013, A Night at The Forum, featuring a private performance by the legendary Eagles, was held to commemorate the re-opening of the newly renovated Forum in California. This sold-out event raised close to $2.5 million for research.

Beyond the support we’ve received through our walks and events, we are incredibly grateful for the generosity of our thousands of individual and corporate donors whose outright gifts have been so instrumental to the Foundation’s growth. These gifts, in addition to the substantial financial support provided by Cablevision, have profoundly impacted the amount of research we can fund in areas including earlier detection and new treatments. We have recently received multimillion dollar bequests from the estates of Walter B. Wriston and Mary Brenneisen. We closed out 2017 with a multimillion dollar corporate gift from Creative Bath Products, Inc. These substantial bequests and gifts are making a difference in the research we can fund that can impact patients and their loved ones.

Looking Ahead

As we embrace the future, we are proud to report that we have directed $165 million to research to date, including an unprecedented $40 million in 2017-2018 alone. We are continuing to make large-scale commitments to leading pancreatic cancer researchers, funding studies that seek to stretch the boundaries of science. We have established a private fund for administrative expenses to replace Cablevision’s support, so that we can continue to direct 100% of every donation to pancreatic cancer research.

We will continue to focus our research program on the areas that will have the greatest impact for patients: earlier detection and early intervention; personalized medicine; and new therapies. For our earlier detection and early intervention program, we are working to move forward the routine blood test in the doctor’s office (CancerSEEK), advance imaging capabilities to pick up tumors when they are smaller, and test innovative neoadjuvant (before surgery) therapies so patients with locally advanced pancreatic cancer who would generally not be operable can have surgery.

We are supporting research that advances personalized medicine by using new technologies to conduct genetic sequencing in order to identify existing medicines and new therapy combinations that are most likely to improve patient outcomes.

We are unwaveringly committed to the guiding principle that it is our duty to change patients’ lives, create a larger community of survivors, and give patients reasons to have an abundance of hope. We believe it’s no longer a matter of “if” we are going to conquer this disease. It’s a matter of when.

Learn More

Pancreatic Cancer News


Pancreatic cancer: Mutable cancer cells are more dangerous

7. 8. 18 ladmin

Pancreatic cancer often spreads, forming metastases in the liver or lungs. The prognosis is better for patients with metastases in the lungs. However, the organ that is more likely to be affected depends on the cancer cells’ ability to alter their characteristics and shape – as a research team at the Technical University of Munich (TUM) has discovered.

Pancreatic surveillance identified resectable cancers

30. 7. 18 ladmin

Long-term pancreatic surveillance of high-risk patients identified cancers while they were still resectable, and 85% of such patients remained alive 3 years after diagnosis, researchers reported. An artist’s rendering of a body, with the pancreas shown in red. “Among individuals undergoing pancreatic surveillance, specific detectable lesions with worrisome features predicted neoplastic progression. The short-term outcomes […]

How to Minimize Pancreatic Cancer Risk

23. 7. 18 ladmin

As an avid reader of obituaries, I’ve been struck by how many people these days are succumbing to pancreatic cancer, a cancer long considered rare.

And relatively speaking, it is still rare, accounting for just 3 percent of all cancers. But it is also one of the deadliest because symptoms almost never develop until the disease is advanced and incurable.

Although 55,440 cases, affecting 29,200 men and 26,240 women, are expected to be diagnosed this year in the United States, 44,330 people will die of it, often within months of diagnosis, making it the fourth leading cause of cancer deaths in this country (after lung, colorectal and breast cancer). Furthermore, it is on track to become the second most deadly cancer by 2030.

Breath test analysis spots pancreatic cancer

18. 7. 18 ladmin

Identifying certain compounds found in breath samples helped distinguish patients with pancreatic cancer from those without, according to research published in the British Journal of Surgery.

George Hanna, PhD, FRCS , of the department of surgery and cancer at Imperial College in London, and colleagues wrote the role of these volatile organic compounds (VOC) found in the breath have been studied in other cancers in the past.

The right diet can boost potency of cancer drugs

11. 7. 18 ladmin

Boosting the power of some cancer drugs could be as simple as modifying what you eat, according to two recent studies in mice. The results are the latest from an ongoing push to harness the body’s metabolism to fight cancer.

A study1 published on 11 July in Nature finds that supplementing mouse chow with the amino acid histidine made a chemotherapy called methotrexate more effective against leukaemia cells. Histidine, which is particularly rich in foods like meat and beans, can be given as a nutritional supplement.

Top oncologist to study effect of diet on cancer drugs

6. 7. 18 ladmin

A groundbreaking clinical trial on whether diet could boost the effectiveness of cancer drugs is set to be launched by one of the world’s leading oncologists.

The work, led by Siddhartha Mukherjee at Columbia University Medical Center in New York, will investigate whether a high-fat, low-carbohydrate diet could improve outcomes for patients with lymphoma and endometrial cancer.